Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain.
CD8+ T-cells
PET/CT imaging
immune checkpoint inhibitors
melanoma
toxicity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
04
2023
accepted:
18
05
2023
medline:
20
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Treatment with immune checkpoint inhibitors (ICI) can induce durable responses in cancer patients, but it is commonly associated with serious immune-related side effects. Both effects are suggested to be mediated by CD8+ T-cell infiltration. Whole body CD8+ T-cell distribution can be visualized by PET imaging of a 89Zr-labeled anti-humanCD8a minibody, currently investigated in a phase 2b trial. An adult patient diagnosed with metastatic melanoma developed ICI-related hypophysitis after two courses of combined immunotherapy (ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) at 3 weeks interval). On a [ The observations in this case report underscore the role of CD8+ T-cell in non-tumor tissues in ICI-related toxicity. In addition, it illustrates a potential role for molecular imaging by PET/CT for investigation and monitoring of ICI-induced effects.
Sections du résumé
Background
Treatment with immune checkpoint inhibitors (ICI) can induce durable responses in cancer patients, but it is commonly associated with serious immune-related side effects. Both effects are suggested to be mediated by CD8+ T-cell infiltration. Whole body CD8+ T-cell distribution can be visualized by PET imaging of a 89Zr-labeled anti-humanCD8a minibody, currently investigated in a phase 2b trial.
Main body
An adult patient diagnosed with metastatic melanoma developed ICI-related hypophysitis after two courses of combined immunotherapy (ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) at 3 weeks interval). On a [
Conclusions
The observations in this case report underscore the role of CD8+ T-cell in non-tumor tissues in ICI-related toxicity. In addition, it illustrates a potential role for molecular imaging by PET/CT for investigation and monitoring of ICI-induced effects.
Identifiants
pubmed: 37334384
doi: 10.3389/fimmu.2023.1199282
pmc: PMC10272360
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Zirconium-89
NTM296JU95
Radioisotopes
0
Zirconium
C6V6S92N3C
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199282Informations de copyright
Copyright © 2023 Bol, Peeters, van Herpen, Westdorp and Aarntzen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
AJNR Am J Neuroradiol. 2020 Sep;41(9):1683-1689
pubmed: 32763900
J Clin Oncol. 2017 Dec 1;35(34):3815-3822
pubmed: 28915085
Front Immunol. 2022 Apr 26;13:779691
pubmed: 35558065
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
Clin Cancer Res. 2009 Apr 1;15(7):2507-13
pubmed: 19318477
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Front Oncol. 2022 Mar 08;12:836859
pubmed: 35350573
J Nucl Med. 2022 May;63(5):720-726
pubmed: 34413145